Cowen & Co. Remains a Buy on Curis Inc (CRIS)


Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Curis Inc (NASDAQ: CRIS) yesterday. The company’s shares closed yesterday at $1.62, close to its 52-week low of $1.36.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 7.6% and a 39.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Curis Inc with a $8 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.70 and a one-year low of $1.36. Currently, Curis Inc has an average volume of 244.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts